Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E
NCI-MATCH subprotocol Z1E demonstrates that larotrectinib offers clinically significant benefit with marked ORR across <i>NTRK</i> fusion-positive tumors with no clinically significant toxicities. These findings support the rationale for the US Food and Drug Administration's tissue-agnostic approval of larotrectinib for <i>NTRK</i> fusion-positive tumors. Our findings demonstrate the necessity of including <i>NTRK1</i>, <i>NTRK2</i>, and <i>NTRK3</i> within comprehensive molecular assays of cancer to navigate patients to an easily administered and highly effective therapy.
Authors
- Neal S. Akhave (ORCID: https://orcid.org/0000-0002-1291-0218)
- David R. Patton (ORCID: https://orcid.org/0000-0003-3855-0166)
- Stanley R. Hamilton (ORCID: https://orcid.org/0000-0002-8331-1052)
- Zihe Song
- James V. Tricoli
- David S. Hong
- V. Wang
- Keith T. Flaherty
- Carlos L. Arteaga
- Lisa M. McShane
- Alice P. Chen
- Naoko Takebe
- Peter J. O'Dwyer
- Lyndsay N. Harris
- P. Mickey Williams
- Robert J. Gray
- Barbara A. Conley
Institutions
- City Of Hope National Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Massachusetts General Hospital (US)
- Southwestern Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Frederick National Laboratory for Cancer Research (US)
- National Cancer Institute (US)
- Harold C. Simmons Comprehensive Cancer Center
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1200/po-25-00612
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00